Casey Lynch (L) and Chris Lowe, Cortexyme's outgoing and interim CEOs

Trou­bled Alzheimer's play­er Cor­texyme says good­bye to found­ing team as in­de­pen­dent in­vestor takes chair­man­ship

When Cor­texyme’s lead­er­ship got on an an­a­lyst call last Oc­to­ber to dis­cuss the re­sults for their lead Alzheimer’s drugs, many lis­ten­ers were be­wil­dered.

The tri­al had un­equiv­o­cal­ly failed: No dif­fer­ence in cog­ni­tive de­cline was seen be­tween pa­tients on place­bo and pa­tients on their drug. There did seem to be an ef­fect on one sub­group that some neu­rol­o­gists found promis­ing, but that was just the ten­ta­tive ba­sis for a new study, not a de­ci­sive re­sult.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.